The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Subscribe To Our Newsletter & Stay Updated
